67 related articles for article (PubMed ID: 38564630)
1. Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer.
Sun L; Zhou H; Yang Y; Chen J; Wang Y; She M; Li C
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32329507
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis and validation reveal DEPDC1 as a potential diagnostic biomarker associated with tumor immunity in non-small-cell lung cancer.
Lv M; Li X; Yin Z; Yang H; Zhou B
PLoS One; 2024; 19(4):e0294227. PubMed ID: 38564630
[TBL] [Abstract][Full Text] [Related]
3. STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis.
Liu C; Li X; Hao Y; Wang F; Cheng Z; Geng H; Geng D
Aging (Albany NY); 2020 May; 12(9):8680-8701. PubMed ID: 32396871
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. [DEPDC1 is Highly Expressed in Lung Adenocarcinoma and Promotes Tumor Cell Proliferation].
Shen J; Xi M
Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):453-460. PubMed ID: 34134185
[TBL] [Abstract][Full Text] [Related]
6. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA KTN1 antisense RNA 1exerts an oncogenic function in lung adenocarcinoma by regulating DEP domain containing 1 expression via activating epithelial-mesenchymal transition.
Li YY; Li W; Chang GZ; Li YM
Anticancer Drugs; 2021 Jun; 32(6):614-625. PubMed ID: 33491970
[TBL] [Abstract][Full Text] [Related]
8. Biocompatible Porphyrin-Peptide Conjugates as Theranostic Agents Targeting the Epstein-Barr Virus.
Li X; Xie C; Zha S; Tam WS; Jiang M; Wong KL
Chempluschem; 2022 Aug; 87(11):e202200184. PubMed ID: 36036545
[TBL] [Abstract][Full Text] [Related]
9. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment.
Reda M; Ngamcherdtrakul W; Nelson MA; Siriwon N; Wang R; Zaidan HY; Bejan DS; Reda S; Hoang NH; Crumrine NA; Rehwaldt JPC; Bindal A; Mills GB; Gray JW; Yantasee W
Nat Commun; 2022 Jul; 13(1):4261. PubMed ID: 35871223
[TBL] [Abstract][Full Text] [Related]
10. NCAPH is a prognostic biomarker and associated with immune infiltrates in lung adenocarcinoma.
Li C; Meng J; Zhang T
Sci Rep; 2022 Jun; 12(1):9578. PubMed ID: 35688915
[TBL] [Abstract][Full Text] [Related]
11. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.
Kaptein P; Jacoberger-Foissac C; Dimitriadis P; Voabil P; de Bruijn M; Brokamp S; Reijers I; Versluis J; Nallan G; Triscott H; McDonald E; Tay J; Long GV; Blank CU; Thommen DS; Teng MWL
Sci Transl Med; 2022 Apr; 14(642):eabj9779. PubMed ID: 35476594
[TBL] [Abstract][Full Text] [Related]
12. Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment.
Wei B; Feng H; Wu H
Int J Gen Med; 2022; 15():3043-3053. PubMed ID: 35308572
[TBL] [Abstract][Full Text] [Related]
13. Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.
Hsiao SH; Chen WT; Chung CL; Chou YT; Lin SE; Hong SY; Chang JH; Chang TH; Chien LN
Cancer Med; 2022 May; 11(10):2067-2078. PubMed ID: 35274494
[TBL] [Abstract][Full Text] [Related]
14. MUC20 as a novel prognostic biomarker in ccRCC correlating with tumor immune microenvironment modulation.
Xue B; Guo WM; Jia JD; Kadeerhan G; Liu HP; Bai T; Shao Y; Wang DW
Am J Cancer Res; 2022; 12(2):695-712. PubMed ID: 35261796
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
